Cisplatin / carboplatin API

Intas Pharmaceuticals (Ahmedabad Gujarat India; privately held; founded 1976 by Hasmukh Chudgar; ~$2.4B revenue est. 2022) is the world's largest manufacturer of cisplatin and carboplatin APIs and one of India's largest private pharmaceutical companies. Intas operates its international generic injectable business under the brand Accord Healthcare (UK-registered subsidiary). Intas's Ahmedabad/Sanand API manufacturing complex in Gujarat was the single most important source of cisplatin API for the US market, supplying an estimated 50-60% of US cisplatin imports from its Gujarat facilities. In November 2022, FDA investigators conducting a pre-approval inspection at Intas's Ahmedabad manufacturing facility (FEI 3003889748) discovered hundreds of trash bags filled with shredded quality-control documents — evidence of deliberate document destruction intended to conceal data integrity violations. FDA issued a Form 483 with 10 observations. The FDA subsequently issued a Warning Letter in December 2022. Intas voluntarily ceased API production at the facility. The resulting API supply gap triggered the worst US oncology drug shortage in a decade, beginning in February 2023 for cisplatin and April 2023 for carboplatin. The Intas-Accord shortage became the central case study for pharmaceutical supply chain concentration risk.

Pfizer Inc. (New York NY; NYSE: PFE; ~$58B revenue 2023) is the largest seller of finished cisplatin and carboplatin injectable products in the US market, marketed under the Hospira brand (acquired 2015 for $17B). Pfizer's McPherson Kansas facility (formerly Hospira) is the primary US manufacturing site for cisplatin and carboplatin finished injectable vials. Pfizer sources cisplatin/carboplatin API primarily from Indian manufacturers, historically including Intas/Accord. When Intas shut down API production in late 2022, Pfizer was among the most directly affected finished-dose manufacturers and a primary party in FDA shortage communications. Pfizer's Hospira business is the largest US generic injectable manufacturer across multiple therapeutic categories.

Fresenius Kabi AG (Bad Homburg, Hessen Germany; subsidiary of Fresenius SE & Co. KGaA; ~€9B revenue) is one of the two largest US suppliers of injectable opioid vials for hospital use. Fresenius Kabi's US pharmaceutical manufacturing includes morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection. US manufacturing sites: Wilson NC (large sterile fill-finish campus) and Grand Island NE. Fresenius Kabi was one of the companies hit by the FDA's heightened enforcement of injectable GMP standards in the 2010s. The Wilson NC facility received FDA Warning Letters for sterile manufacturing deficiencies — a pattern common across the injectable pharmaceutical industry. Fresenius Kabi also produces IV fluids, parenteral nutrition, and biosimilars from its US sites, making it a broad-spectrum hospital injectable supplier whose opioid vial lines compete for the same cleanroom capacity as other critical parenteral products.

Teva Pharmaceutical Industries Ltd. (Tel Aviv Israel; NYSE: TEVA; ~$15.9B revenue 2023; world's largest generic pharmaceutical company by revenue) is a significant manufacturer and distributor of generic carboplatin injectable in the US market. Teva's API division (TAPI) and finished-dose operations supply generic oncology products including carboplatin to US hospital pharmacies. Teva experienced its own FDA enforcement actions in this period — in 2022, Teva's Irvine California facility was shut down due to contamination and sterilization failures, causing a separate streptozocin (pancreatic cancer drug) shortage. Teva's manufacturing is concentrated in Israel, India, and Eastern Europe, with US finished-dose manufacturing in North America. Teva's scale as the world's largest generic company makes it a critical backstop supplier when primary market participants face disruptions.

Johnson Matthey PLC (London UK; LSE: JMAT; ~£15.4B revenue FY2023) is a specialty chemicals and platinum group metals refining and processing company, and a critical upstream supplier of pharmaceutical-grade platinum compounds used in cisplatin and carboplatin synthesis. Johnson Matthey's Pharmaceutical Materials and Services division supplies refined platinum salts, chloroplatinic acid, and platinum chemical intermediates to API manufacturers for cisplatin (cis-diamminedichloroplatinum(II)) and carboplatin synthesis. Johnson Matthey is one of the world's principal platinum refiners, processing platinum from South African miners (Anglo American Platinum, Sibanye-Stillwater, Impala Platinum) into the high-purity platinum chemicals required for pharmaceutical synthesis. Johnson Matthey also manufactures autocatalysts for vehicle emissions control — the same platinum group metals supply chain serves both pharmaceutical cisplatin synthesis and catalytic converters.